We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 58

Indian Supreme Court rules Novartis cancer drug change not patentable
  • Shook Hardy & Bacon LLP
  • India
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also


U.S. Trade Rep launches WTO action against India
  • Shook Hardy & Bacon LLP
  • USA, India
  • February 13 2014

U.S. Trade Representative Michael Froman has announced that the United States has requested dispute settlement consultations with India before the


Indian pharma interests challenge U.S. allegations of discriminatory treatment
  • Shook Hardy & Bacon LLP
  • India, USA
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against


India to consider ban on importing animal-tested cosmetics
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Following the June 2013 decision to prohibit the testing of domestically produced cosmetics and their ingredients on animals (details about which


Indian officials to scrutinize pharmaceutical M&As
  • Shook Hardy & Bacon LLP
  • India
  • October 20 2011

Indian ministry officials have apparently decided that foreign companies may continue to invest in new pharmaceutical industry projects but that foreign proposals for mergers and acquisitions in this sector will have to undergo enhanced scrutiny


Indian biotech association signs MOU with U.S.-based association
  • Shook Hardy & Bacon LLP
  • India, USA
  • October 18 2012

The Association of Biotechnology Led Enterprises (ABLE), representing biotechnology interests in India, has reportedly signed a memorandum of understanding (MOU) with the Washington Biotechnology and Biomedical Association (WBBA), Washington state’s life-sciences trade association


Drug makers complain about slow regulatory approvals in India
  • Shook Hardy & Bacon LLP
  • India, Global
  • February 21 2013

Pharmaceutical companies have reportedly begun shifting their clinical trials out of India, claiming that bureaucrats have been slow to approve them


Indian Parliament considers bill to regulate drugs and cosmetics
  • Shook Hardy & Bacon LLP
  • India
  • September 12 2013

Officials in India have introduced a bill that would establish a Central Drugs Authority (CDA) headed by the secretary of health and family


India-based company’s drugs barred from U.S. market
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 30 2014

The U.S. Food and Drug Administration (FDA) has prohibited imported drug products from a Ranbaxy Laboratories, Inc. facility in India due to


India to ban PET packaging for certain pharmaceuticals
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of